Methodological standard · §7
CEI-MS-21 — references
Normative and informative references, and related standards in the same category.
§7References
§7.1Normative references
The following are normative for this standard: compliance with the standard requires compliance with them[1,2].
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products — ICH Harmonised Tripartite Guideline, 2003
- ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products — ICH Harmonised Tripartite Guideline, 1999
§7.2Informative references
The following are informative: they support the reasoning of the standard without being conditions of compliance[3,4,5].
- Stability of protein pharmaceuticals: an update — Pharmaceutical Research, 2010
- Protein aggregation — pathways and influencing factors — International Journal of Pharmaceutics, 2010
- Rational design of stable lyophilized protein formulations: some practical advice — Pharmaceutical Research, 1997
§7.3Related standards
- CEI-MS-20 — Photostability assessment of light-sensitive peptides
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- Wang W, Nema S, Teagarden D. Protein aggregation — pathways and influencing factors. International Journal of Pharmaceutics 2010;390(2):89–99. doi:10.1016/j.ijpharm.2010.02.025 · PMID 20188795
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceutical Research 1997;14(8):969–975. doi:10.1023/a:1012180707283 · PMID 9279875
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-MS-21/7 · https://compoundevidence.com/methods/freeze-thaw/references/ · retrieved 30 July 2026